GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » Debt-to-Equity

SHTDF (Sinopharm Group Co) Debt-to-Equity : 1.34 (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Debt-to-Equity?

Sinopharm Group Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $11,227 Mil. Sinopharm Group Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $2,702 Mil. Sinopharm Group Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $10,413 Mil. Sinopharm Group Co's debt to equity for the quarter that ended in Jun. 2024 was 1.34.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sinopharm Group Co's Debt-to-Equity or its related term are showing as below:

SHTDF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.96   Med: 1.19   Max: 1.7
Current: 1.34

During the past 13 years, the highest Debt-to-Equity Ratio of Sinopharm Group Co was 1.70. The lowest was 0.96. And the median was 1.19.

SHTDF's Debt-to-Equity is ranked worse than
84.04% of 94 companies
in the Medical Distribution industry
Industry Median: 0.375 vs SHTDF: 1.34

Sinopharm Group Co Debt-to-Equity Historical Data

The historical data trend for Sinopharm Group Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Debt-to-Equity Chart

Sinopharm Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.16 1.22 1.11 1.02 0.99

Sinopharm Group Co Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 1.02 1.36 0.99 1.34

Competitive Comparison of Sinopharm Group Co's Debt-to-Equity

For the Medical Distribution subindustry, Sinopharm Group Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co's Debt-to-Equity Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Debt-to-Equity falls into.



Sinopharm Group Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sinopharm Group Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sinopharm Group Co's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co  (OTCPK:SHTDF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Sinopharm Group Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 07-30-2020

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon 10-18-2014

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 01-25-2021

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon 05-19-2016

Sinopharm Group Co Ltd's Dividend Analysis

By GuruFocus Research 06-17-2024